MorphoSys AG (NASDAQ:MOR) Q4 2019 Earnings Conference Call - Final Transcript

Mar 19, 2020 • 09:00 am ET


MorphoSys AG (NASDAQ:MOR) Q4 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, welcome to the MorphoSys Year-End Results 2019. Please note that for the duration of the presentation, all participants will be in a listen-only mode, and the conference is being recorded. [Operator Instructions]

Now, I would like to turn over the conference over to Dr. Julia Neugebauer. Please go ahead.

Dr. Julia Neugebauer

Good afternoon, good morning, and welcome to our 2019 full-year results conference call and webcast. My name is Julia Neugebauer, Director of Corporate Communications and Investor Relations at MorphoSys. With me on the call today are Jean-Paul Kress, our Chief Executive Officer; Jens Holstein, our Chief Financial Officer; and Malte Peters, our Chief Research and Development Officer.

Please note that due to the COVID-19 pandemic, we are dialing-in from different location. So, I would like to apologize for any disruptions this might cause, and we just learnt that there seems to be technical issues with the U.S. dial-in. So, please, if this does not work, use the U.K. or German dial-in.

Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of MorphoSys' core technologies, the progress of its current research and development programs, our transition to a fully-integrated commercial pharmaceutical company, and initiation of additional programs. Should actual conditions differ from the company's assumptions, actual results and actions may differ from those anticipated. You are therefore cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

You can find the agenda for today's call on Page 3. Jean-Paul will start with his opening remarks and an update on our commercial capability. He will then handover to Malte, who will discuss R&D progress we have made in 2019, especially for tafasitamab. Jens will review the financial results for 2019 and present the financial guidance for 2020. Jean-Paul then will close with the outlook for 2020. After the presentation, we will all be available for your questions. You will find the slide deck for this call on our corporate Web site.

I would now like to hand over to Jean-Paul.

Dr. Jean-Paul Kress

Thank you, Julia. First, I would like to thank you all for joining our call in these challenging circumstances. We are all facing difficult and stressful times with this pandemic crisis, a major threat to public health to business continuity and to our economy. Going to be tough for some time, but I am convinced that we all together will beat the virus.

We at MorphoSys are staying laser-focused on delivering on our strategic goals and on our mission to bring outstanding medicines to patients suffering from severe diseases. We are in a favorable position as we have already filed our BLA for tafasitamab in many of the relapsed/refractory DLBCL patients of a very poor prognosis, and our primary goal continues to be achieving a complete response, despite the risks.

Now, let me move to our 2019 highlights. 2019 was a very successful year for MorphoSys. We